Since joining PaxVax in 2011, Nima Farzan has helped the company carve out a distinct position in the vaccines market while assembling a world-class team with expertise from key industry and US government organizations. He sets strategy and direction for PaxVax, leading a company that develops, manufactures and commercializes specialty vaccines for neglected markets.
As a thought leader, Mr. Farzan speaks about the innovative role that vaccines play in the prevention of infectious diseases worldwide, and has driven the company’s achievements in protecting against some of the world’s biggest public health challenges. Mr. Farzan serves on the boards of PaxVax and the Coalition for Epidemic Preparedness Innovations (CEPI), a new public-private alliance designed to prevent public health emergencies and contain global epidemics as the Biotechnology Innovation Organization (BIO) delegate.
Under his leadership, Mr. Farzan has fostered the commercialization of products including Vaxchora and Vivotif, and secured more than $105 million investment from Cerberus Capital Management, helping establish the long-term trajectory for the company and facilitating its focus on growth.
Mr. Farzan joined PaxVax from Novartis AG where he spent more than seven years in a number of positions of increasing responsibility including pharmaceutical marketing, sales, and development in both global and US positions.
In his previous role prior to leaving Novartis, Mr. Farzan served as the Vice President of Marketing for the vaccines business unit of Novartis, where he was responsible for marketing, market access, pricing, and key account sales and helped launch multiple new vaccines. Prior to Novartis, Mr. Farzan worked at DoubleTwist, a genomics company, and was a consultant at The Boston Consulting Group. He is a member of Young Presidents Organization (YPO) and holds a Masters of Business Administration from Harvard Business School and a Bachelor of Arts degree in Human Biology from Stanford University.
Under Mr. Farzan’s leadership, PaxVax remains committed to making its vaccines available for use for the developing world to protect against endemic infectious diseases and ensure we can increase access to these vaccines for the people who need them most.